352 related articles for article (PubMed ID: 14663031)
1. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease.
Thal LJ; Grundman M; Berg J; Ernstrom K; Margolin R; Pfeiffer E; Weiner MF; Zamrini E; Thomas RG
Neurology; 2003 Dec; 61(11):1498-502. PubMed ID: 14663031
[TBL] [Abstract][Full Text] [Related]
2. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease.
Weyer G; Babej-Dölle RM; Hadler D; Hofmann S; Herrmann WM
Neuropsychobiology; 1997; 36(2):73-82. PubMed ID: 9267856
[TBL] [Abstract][Full Text] [Related]
3. Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study.
Gutzmann H; Hadler D
J Neural Transm Suppl; 1998; 54():301-10. PubMed ID: 9850939
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
Gutzmann H; Kühl KP; Hadler D; Rapp MA
Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153
[TBL] [Abstract][Full Text] [Related]
5. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Morris JC; Cyrus PA; Orazem J; Mas J; Bieber F; Ruzicka BB; Gulanski B
Neurology; 1998 May; 50(5):1222-30. PubMed ID: 9595967
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.
Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Petanceska S; Browne P; Wassar D; Johnson-Traver S; Lochhead J; Ziolkowski C
Curr Alzheimer Res; 2005 Jul; 2(3):343-53. PubMed ID: 15974900
[TBL] [Abstract][Full Text] [Related]
7. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD.
Thal LJ; Calvani M; Amato A; Carta A
Neurology; 2000 Sep; 55(6):805-10. PubMed ID: 10994000
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
9. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
[TBL] [Abstract][Full Text] [Related]
10. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
11. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study.
Mulnard RA; Cotman CW; Kawas C; van Dyck CH; Sano M; Doody R; Koss E; Pfeiffer E; Jin S; Gamst A; Grundman M; Thomas R; Thal LJ
JAMA; 2000 Feb; 283(8):1007-15. PubMed ID: 10697060
[TBL] [Abstract][Full Text] [Related]
12. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
[TBL] [Abstract][Full Text] [Related]
13. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia.
Kennedy J; Deberdt W; Siegal A; Micca J; Degenhardt E; Ahl J; Meyers A; Kaiser C; Baker RW
Int J Geriatr Psychiatry; 2005 Nov; 20(11):1020-7. PubMed ID: 16250069
[TBL] [Abstract][Full Text] [Related]
14. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
15. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
Thal LJ; Schwartz G; Sano M; Weiner M; Knopman D; Harrell L; Bodenheimer S; Rossor M; Philpot M; Schor J; Goldberg A
Neurology; 1996 Dec; 47(6):1389-95. PubMed ID: 8960716
[TBL] [Abstract][Full Text] [Related]
16. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
17. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.
Lawlor B; Segurado R; Kennelly S; Olde Rikkert MGM; Howard R; Pasquier F; Börjesson-Hanson A; Tsolaki M; Lucca U; Molloy DW; Coen R; Riepe MW; Kálmán J; Kenny RA; Cregg F; O'Dwyer S; Walsh C; Adams J; Banzi R; Breuilh L; Daly L; Hendrix S; Aisen P; Gaynor S; Sheikhi A; Taekema DG; Verhey FR; Nemni R; Nobili F; Franceschi M; Frisoni G; Zanetti O; Konsta A; Anastasios O; Nenopoulou S; Tsolaki-Tagaraki F; Pakaski M; Dereeper O; de la Sayette V; Sénéchal O; Lavenu I; Devendeville A; Calais G; Crawford F; Mullan M;
PLoS Med; 2018 Sep; 15(9):e1002660. PubMed ID: 30248105
[TBL] [Abstract][Full Text] [Related]
18. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial.
Rockwood K; Mintzer J; Truyen L; Wessel T; Wilkinson D
J Neurol Neurosurg Psychiatry; 2001 Nov; 71(5):589-95. PubMed ID: 11606667
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease.
Pasqualetti P; Bonomini C; Dal Forno G; Paulon L; Sinforiani E; Marra C; Zanetti O; Rossini PM
Aging Clin Exp Res; 2009 Apr; 21(2):102-10. PubMed ID: 19448381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]